Prevention and treatment of chlamydiosis and cryptococcosis in koalas


Australian post-graduate award (industry) on pig production and vaccination

(2 scholarships available)


Dr Trish Holyoake (02) 93511617

Dr Alison Collins (02) 46406306

Dr David Emery (02) 9351 3102

The problem

Proliferative enteropathy (PE) is a major profit-limiting disease for pig producers globally. The disease costs pork producers in Australia up to $7.00 per pig, adding almost 5% to the total cost of production. Much of this cost is due to the widespread use of antibiotics in the grower and finisher diets to treat and prevent PE, and veterinarians and producers are reticent to remove or change the medication as this often results in an increased occurrence of PE. There are increasing public concerns regarding the amplification of antibiotic resistant bacteria and the impact on human health. Whenever antibiotics are used there is a potential for selection of antibiotic resistant strains of bacteria. Pigs are major consumers of antibiotics. Clearly, there is a need for an alternative to antibiotics for the control of PE.

The solution

Boehringer Ingelheim Pty Limited Australia is a member of the Boehringer Ingelheim group of companies, with headquarters in Ingelheim, Germany. It is one of the 20 leading pharmaceutical, chemical and biological firms in the world, with 140 affiliated companies worldwide focusing on human pharmaceuticals and animal health. They are the only pharmaceutical animal health company in the world to develop and register a vaccine (Enterisol® Ileitis) to aid in the control of

PE in pigs. This vaccine is registered for use in a number of overseas countries and is currently being reviewed by the Australian Pesticides and Veterinary Medicines Authority (APVMA) for registration in Australia.

Researchers at the University of Sydney, NSW Department of Primary Industries and Boehringer

Ingelheim have developed a collaborative research project to reduce antibiotic usage in pig herds by controlling PE in pigs by vaccination, housing and hygiene.

The scholarships

Two full-time PhD scholarships are being funded by an ARC Linkage-Projects grant for 3 years to be based primarily at the Camden campus .

During the course of the project, the PhDs will:

study the immune response of Enterisol ®-vaccinated pigs using cutting edge technology to optimise the protective immune response in vaccinated pigs under Australian conditions

Use the CT scanner to visualise intestinal pathology and determine the effect of infection on carcass composition of pigs

visit Boehringer Ingelheim in Germany and learn more about the process of commercial vaccine development

attend conferences in Australia and overseas to present the results of your research

 work with some of Australia’s leading experts in pork production, immunology and microbiology

Applicants should have an Honours 1 or 2A degree in veterinary science, animal science or agricultural science. An interest in immunology and/or epidemiology and how it applies to pig health and production would be an advantage. Applicants must be Australian citizens, Australian permanent residents or New Zealand citizens. The scholarship stipend is $24,650* p.a. in 2005

(tax exempt). For further information, contact Dr Trish Holyoake, Dr David Emery or Dr Alison

Collins. Applications, including a curriculum vitae, copy of an academic transcript, proof of citizenship or permanent residency, the names and contact details of at least two referees should be sent to Dr Trish Holyoake, Faculty of Veterinary Science, The University of Sydney, 425

Werombi Rd, Camden NSW 2550. Closing Date: 31 st January 2006. These scholarships are subject to signing of contracts between the University of Sydney and the commercial partners.

* $24,650 for L-P grants commencing in 2005. ARC has not announced the 2006 rate as at 17 November 2005.